Antidepressant digital therapy (deprexis®) effective in the US
Hamburg, Germany: GAIA AG, a global pioneer in digital therapy, announced today that deprexis®, a software developed by Gaia, has been demonstrated to be effective in a scientific study in the US.
A randomized controlled trial (RCT) with N = 376 depressed adults, published in the latest issue of the Journal of Consulting and Clinical Psychology, has confirmed that deprexis is effective in the United States. The trial was led by Professor Christopher Beevers, Director of the Institute of Mental Health Research at the University of Texas, Austin. With an impressive effect size of d=0.80 (large effect), the study provides evidence that deprexis is at least as effective in the United States as in seven previous Europe-based trials.
The researchers concluded that participants who received deprexis had a “12 times greater likelihood of experiencing at least 50% symptom improvement compared with waitlist control”. The deprexis effect was also replicated in the control group: After they received access to deprexis, similar depression reductions as those in the immediate treatment group were observed, confirming the robustness of the deprexis effect.
“The results of this trial provide even more scientific evidence for the effectiveness of our digital therapeutics, now specifically in the US”, said Mario Weiss, CEO and founder of GAIA. “Several thousand patients have now taken part in deprexis studies around the world. We believe it is necessary to go to such lengths so that physicians, psychotherapists and patients can be confident they are using an effective tool.” Deprexis is globally licensed to Servier, except in the USA and Japan.
GAIA is a global leader in digital therapeutics with a broad pipeline of products at different development stages. With its declared focus on research and development of evidence-based online interventions, the company continuously shifts benchmarks when it comes to efficacy and safety profiles for digital therapeutics in neuroscience. With more than 100 experts in the fields of medicine, psychology, behavioral medicine, software engineering, as well as regulatory and market access, GAIA is a key partner in the development of next-generation digital solutions to support and treat patients with a broad variety of medical conditions.
More information: http://gaia-group.com/en
+49 40 3510520
This release was published on openPR.
Permanent link to this press release:
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Antidepressant digital therapy (deprexis®) effective in the US here
News-ID: 455334 • Views: 1088
More Releases from GAIA AG
JAMA Psychiatry meta-analysis confirms deprexis efficacy
* Gaia AG’s self-guided internet-based cognitive behavioral therapy effective in treating depressive symptoms * Hamburg, Germany: GAIA AG, a global pioneer in digital therapy, announced today that deprexis®, a web-based EC- and FDA-cleared medical device developed by GAIA, has once again been proven to be effective in a global scientific study. A new meta-analysis of individual patient data, published in the latest issue of JAMA Psychiatry, confirmed the efficacy of
Individual Online Help for Depression
Depression is a common and growing disease. People who suffer from such a mental disease are often confronted with additional problems, both in their private and professional lives, as well as in their finances. Losing one’s job, friends and spending a lot of money for high-cost treatment like psychotherapy and medication at the same time add even more pressure to one’s already unhappy circumstances. And this is only the tip of